Tag Archives: FDA

Specialty Drug, Specialty Pharmacy

JNJ’s Multiple Sclerosis Drug Ponvory Available From Covance Specialty Pharmacy

Posted on by John Santilli
26
Mar

The Janssen Pharmaceutical Companies of Johnson & Johnson recently announced that the FDA approved PONVORY™ (ponesimod), a once-daily oral selective sphingosine-1-phosphate receptor 1 (S1P1) modulator, to treat adults with relapsing forms of multiple sclerosis (MS). PONVORY™ offers MS patients superior efficacy in reducing annualized relapse rates compared to an established oral therapy and a proven […]

Continue reading →
LTC Pharmacy, Specialty Drug, Specialty Pharmacy

PharMerica’s Onco360 Selected as Exclusive Specialty Pharmacy Partner for UKONIQ

Posted on by John Santilli
11
Feb

PharMerica is a leading provider of home and community-based health and pharmacy services for high-need and medically complex populations

Continue reading →
Specialty Drug, Specialty HUBs

Eton Pharmaceuticals’ ALKINDI® SPRINKLE is available exclusively through AnovoRx

Posted on by John Santilli
21
Dec

AnovoRx’s focus is intentionally centered on the unique needs of patients with chronic diseases who rely on specialty and orphan drugs as well as manufacturers

Continue reading →
Specialty Drug, Specialty HUBs, Specialty Pharmacy

Centene Strengthens Specialty Pharmacy Rare Disease Position with PantherRx Acquisition

Posted on by John Santilli
15
Dec

Biophama companies are increasingly interested in establishing relationships with  experienced specialty pharmacies to dispense rare disease drugs to patients

Continue reading →
Specialty Drug, Specialty HUBs, Specialty Pharmacy

PantherRx Rare and Orsini Specialty Pharmacy Chosen as Partners for OXLUMO

Posted on by John Santilli
08
Dec

Alnylam® Pharmaceuticals selected PantherRx Rare and Orsini Specialty Pharmacy as limited distribution partners for OXLUMO™ (lumasiran). OXLUMO is the first and only treatment approved for primary hyperoxaluria type 1 (PH1) to lower urinary oxalate levels in pediatric and adult patients. PH1 is an ultra-rare genetic disease characterized by the overproduction of oxalate, a waste product that […]

Continue reading →
Biopharma, Specialty Pharmacy

Rare Diseases and Orphan Drugs Growth Favorable to Specialty Pharmacies

Posted on by John Santilli
02
Dec

Biophama companies are increasingly interested in establishing relationships with  experienced specialty pharmacies to dispense rare disease drugs to patients

Continue reading →
Affordable Care Act, Biosimilar, Health Insurance

ACA Supreme Court Deliberations and Any Impact on Biosimilars?

Posted on by Dr. Randy
28
Nov

If the court strikes down the ACA entirely, biosimilars on the U.S. market or in the FDA approval pipeline would have to either be grandfathered in or face a regulatory wind-down

Continue reading →
Specialty Drug, Specialty Pharmacy

Duchenne Muscular Dystrophy (DMD) Patients Have Choice of Medications

Posted on by John Santilli

The number of chronic infusion therapies for neuromuscular disorders continues to grow

Continue reading →